FDA, the National Organization for Rare Disorders and the Critical Path Institute (C-Path) launched a data analytics platform that the parties hope will accelerate the development of new cures for rare diseases. FDA drug center chief Janet Woodcock said The Rare Disease Cures Accelerator Data And Analytics Platform (RDCA-DAP) is “the best we can do” to speed up rare disease drug development, but she warned the platform will take time to reach its full potential. The new platform has three...